Lo que debes saber sobre Paxlovid para tratar covid, en especial, ¿debes tomarlo?
Desde que Paxlovid comenzó a estar disponible hace siete meses, ha eclipsado otras terapias disponibles para prevenir los síntomas graves de covid en pacientes de alto riesgo. Algunos médicos se apresuran a recetarlo, pero como ocurre con tanto sobre la pandemia de covid, hay controversia.
Everything You Need to Know About Paxlovid — Especially, Should You Take It?
Paxlovid has eclipsed other available therapies for preventing life-threatening covid symptoms in high-risk patients. But even as doctors praise its effectiveness, many say they have unanswered questions about prescribing the drug and want more and better data about it.
KHN’s ‘What the Health?’: Drug Price Bill Is a Go in the Senate
Two things happened in Washington this week that were inevitable: President Joe Biden tested positive for covid-19, and the Senate agreed to move forward on a budget bill that includes only a sliver of what Biden hoped it would. Still, the bill to allow Medicare to negotiate some drug prices, cap out-of-pocket drug costs for seniors, and extend temporary subsidies for Affordable Care Act insurance premiums would represent a major step if Democrats can get it across the finish line. Meanwhile, abortion battles continue to escalate around the country, with Texas leading the way in restrictions. Shefali Luthra of The 19th, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Jack Resneck Jr., the new president of the American Medical Association.
Boost Now or Wait? Many Wonder How Best to Ride Out Covid’s Next Wave
As the country faces a rise in new infections driven by the omicron BA.5 subvariant of the coronavirus, about 70% of people 50 and older who got a first covid-19 booster shot haven’t received the recommended second one, according to the Centers for Disease Control and Prevention. Many undervaccinated Americans have lost interest, and others aren’t sure whether to get boosted again now or wait for vaccines reformulated to target newer strains of the virus.
¿Ponerse el refuerzo ahora o esperar? Muchos se preguntan cómo navegar la próxima ola de covid
Aproximadamente el 70% de los estadounidenses de 50 años o más que recibieron una primera vacuna de refuerzo contra covid, y casi la misma cantidad de personas de 65 años o más, no han recibido un segundo, según datos de los CDC.
A Free-for-All From Readers and Tweeters, From Medical Debt to Homelessness
KHN gives readers a chance to comment on a recent batch of stories.
‘An Arm and a Leg’: One ER Doctor Grapples With the Inequities of US Health Care
This episode is an interview with Dr. Thomas Fisher, author of “The Emergency: A Year of Healing and Heartbreak in a Chicago ER.”
Feds Want Policy That Advocates Say Will Let Hospitals Off the Hook for Covid-Era Lapses
The pandemic disrupted all sense of normalcy for U.S. hospitals, so federal officials are proposing to pause financial penalties against the facilities and to block public access to key hospital safety data — such as the frequency of falls and sepsis — because of concerns that the data isn’t accurate enough. But consumer advocates are furious about the proposal.
How Pfizer Won the Pandemic, Reaping Outsize Profit and Influence
The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success has overshadowed the government’s covid-fighting strategy.
‘My Body, My Choice’: How Vaccine Foes Co-Opted the Abortion Rallying Cry
Anti-vaccine advocates discovered a catchy, succinct, and potent slogan. Its unlikely source: the abortion rights movement.